Sonnet biotherapeutics announces progress in two phase 1 dose-escalation trials of son-1010

The sb101 and sb102 studies have together dosed 19 subjects to date this early review of safety sets the stage for further dose escalation additional safety and cytokine-specific data are expected during the fourth calendar quarter of 2022 princeton, nj / accesswire / september 21, 2022 / sonnet biotherapeutics holdings, inc., (nasdaq:sonn) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that initial safety has been formally reviewed in both phase 1 clinical trials of son-1010(il12-fhab) in adults and that dose escalation is continuing. sb101 is a multiple-dose trial for patients with advanced solid tumors that commenced in april (nct05352750) and has now started treating the third dose cohort.
SONN Ratings Summary
SONN Quant Ranking